Good decisions require good information
Find hidden gems and smart strategies from top experts when you join Seeking Alpha.
AVTX Avalo Therapeutics, Inc.Stock Price & Overview
$11.75
Charts
Quant Ranking
AVTX News
Latest Headlines
Ratings Summary
AVTX Company Profile
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company’s drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
AVTX Revenue
AVTX Earnings Per Share
Earnings Estimates
Earnings Revisions
Rating:
Growth
Rating:
Profitability
Rating:
Momentum
Rating:
52 Week Range
Capital Structure
Trading Data
Dividends
AVTX Ownership
AVTX Peers
Risk
Technicals
Investor Presentations
AVTX SEC Filings
Press Releases
AVTX Income Statement
AVTX Balance Sheet
AVTX Cash Flow Statement
AVTX Long Term Solvency
Discover More
You may be interested in: